KEY TAKEAWAYS
- The study aimed to investigate the efficacy and safety of adding Zolbetuximab to the treatment of patients with CLDN18.2-positive, HER2-negative, GC/GEJ cancer.
- Researchers concluded that incorporating Zolbetuximab with chemo holds promising potential in reshaping treatment paradigms for advanced CLDN18.2-positive GC/GEJ cancer.
The benefit of adding Zolbetuximab to the treatment in patients with Claudin-18 isoform 2 (CLDN18.2)-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJ) is not yet fully elucidated.
Francisco Cezar Aquino de Moraes and the team aimed to assess the efficacy and safety of incorporating Zolbetuximab into the therapeutic regimen for individuals diagnosed with advanced CLDN18.2-positive GC/GEJ cancer.
They performed an inclusive analysis by systematically searching PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) comparing the efficacy of Zolbetuximab plus chemotherapy (chemo) versus chemo alone in treating GC/GEJ adenocarcinoma. Hazard ratios (HRs) or odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were computed for binary endpoints, providing a robust methodology for evaluating the comparative outcomes of the treatment modalities.
About 3 studies involving 1,233 patients were incorporated into the analysis. In the comparison between Zolbetuximab plus chemo and chemo alone, the progression-free survival (PFS) rate showed significance in favor of the Zolbetuximab group, with (HR 0.64; 95% CI 0.49-0.84; P < 0.01) and overall survival (OS) rate (HR 0.72; 95% CI 0.62-0.83; P < 0.01) were significant in favor of the Zolbetuximab group. However, in terms of the Objective Response Rate (ORR), no significant difference was observed (OR 1.15; 95% CI 0.87-1.53; P = 0.34).
The study concluded that incorporating Zolbetuximab alongside chemo holds promising potential in reshaping established treatment paradigms for patients diagnosed with advanced CLDN18.2-positive GC/GEJ cancer, as evidenced by the comprehensive systematic review and meta-analysis of RCTs.
The study is sponsored by Conselho Nacional de Desenvolvimento Científico e Tecnológico, the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, the Pró-Reitoria de Pesquisa e Pós-Graduação da UFPA.
Source: https://pubmed.ncbi.nlm.nih.gov/38383390/
de Moraes FCA, Pasqualotto E, Chavez MP, et.al (2024). Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2024 Feb 21;24(1):240. doi: 10.1186/s12885-024-11980-w. PMID: 38383390; PMCID: PMC10882870.
